Object: We performed a prospective study in 77 patients to evaluate the impact of botulinum toxin (BT) therapy on mental symptoms in patients affected by spasticity, focal dystonia, and hyperhydrosis. Method: 25 patients affected by spasticity (group I) and 52 patients affected by focal dystonia or hyperhydrosis (group II) were included in the study. The patients were evaluated at baseline and 3 months after treatment; we studied the clinical effect of BT with Tsui and Columbia test and Global impression scale in group II and with Medical Research Council Scale (MCR) and Modified Ashworth Scale in group I; all the patients were evaluated by the Center Epidemiological Study Depression (CES-D), Brief Symptoms Inventory (BSI and Attachment Style Questionnaire (ASQ); the group II by IIP-64, Family Apgar Score (FAS); spastic patients’ caregivers were examinated by CES-D. A total of 52 patients (14 in group I and 38 in group II) completed the follow-up. Patients were treated with BT type A (Botox-Allergan USA, Dysport-Ipsen UK) at dosage ranging from 350 to 1000 mouse Units (mU) for Dysport BT and 10 to 100 mU for Botox BT. No significant side effect was observed. Results: No differences were found in obsessive-compulsive trait in both of the groups; however we observed a great percentage of depressed patients in group I (36% with pathological rate in CES-D test and 40% under-threshold depression) and in group II (44% with pathological rate, 40% under-threshold depression), who did not improve after BT therapy. Conclusions: The psychopathological assessment is important to identify depressed patients which could benefit from an add-on drug therapy or from a psychological support in association to BT treatment.

Follow-up of psychological features in patients treated with botulinum toxin type A

OSTACOLI, Luca;FURLAN, Piermaria;DURELLI, Luca
2005-01-01

Abstract

Object: We performed a prospective study in 77 patients to evaluate the impact of botulinum toxin (BT) therapy on mental symptoms in patients affected by spasticity, focal dystonia, and hyperhydrosis. Method: 25 patients affected by spasticity (group I) and 52 patients affected by focal dystonia or hyperhydrosis (group II) were included in the study. The patients were evaluated at baseline and 3 months after treatment; we studied the clinical effect of BT with Tsui and Columbia test and Global impression scale in group II and with Medical Research Council Scale (MCR) and Modified Ashworth Scale in group I; all the patients were evaluated by the Center Epidemiological Study Depression (CES-D), Brief Symptoms Inventory (BSI and Attachment Style Questionnaire (ASQ); the group II by IIP-64, Family Apgar Score (FAS); spastic patients’ caregivers were examinated by CES-D. A total of 52 patients (14 in group I and 38 in group II) completed the follow-up. Patients were treated with BT type A (Botox-Allergan USA, Dysport-Ipsen UK) at dosage ranging from 350 to 1000 mouse Units (mU) for Dysport BT and 10 to 100 mU for Botox BT. No significant side effect was observed. Results: No differences were found in obsessive-compulsive trait in both of the groups; however we observed a great percentage of depressed patients in group I (36% with pathological rate in CES-D test and 40% under-threshold depression) and in group II (44% with pathological rate, 40% under-threshold depression), who did not improve after BT therapy. Conclusions: The psychopathological assessment is important to identify depressed patients which could benefit from an add-on drug therapy or from a psychological support in association to BT treatment.
2005
Ninth International Congress of Parkinson's Disease and Movement Disorders
New Orleans - Louisiana
March 5-8, 2005
20, Issue S10
S51
S51
http://www3.interscience.wiley.com/journal/109924006/issue
Follow-up study; psychological features; botulinum toxin; mental symptoms; spasticity; focal dystonia; and hyperhydrosis; BT treatment; depression; psychological support
Coletti Moja M; Milano E; Ostacoli E; Furlan PM; Durelli L
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/52122
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact